The high frequency of anti-PF4/heparin antibodies in patients with COVID-19 is neither related to heparin treatment or to an increased incidence of thrombosis
Tiffany Pascreau(Inserm), Marc Vasse(Hôpital Foch), Jad Choucair(Hôpital Foch), Roselyne Bironien(Hôpital Foch), Benjamin Zuber(Hôpital Foch), Sara Zia-Chahabi(Hôpital Foch), Éric Farfour(European Foundation for Clinical Nanomedicine), Marie‐Christine Ballester(Hôpital Foch), Patrick Van Dreden(Stago (France))
Cited by 12
Related Papers
International clinical guidelines for the management of phosphomannomutase 2‐congenital disorders of glycosylation: Diagnosis, treatment and follow up
|Journal of Inherited Metabolic Disease|2019|149
Evaluation of the Andromas Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry System for Identification of Aerobically Growing Gram-Positive Bacilli
|Journal of Clinical Microbiology|2012|137
The extravascular compartment of the bone marrow: a niche for Plasmodium falciparum gametocyte maturation?
|Malaria Journal|2012|112
Clinical Assessment of a Nocardia PCR-Based Assay for Diagnosis of Nocardiosis
|Journal of Clinical Microbiology|2018|83